

CBC-3D®
for Melet Schloesing & Dialab
HEMATOLOGY CONTROLS
CONTROL

ASSAY VALUES AND EXPECTED RANGES
 QCP DATA MONTHS: FEBRUARY, MARCH, APRIL

LOT B0223

 2023-05-05

Instrument	Parameter	Low	Normal	High
		LOT B0223L	LOT B0223N	LOT B0223H
Melet Schloesing MS4s	WBC $\times 10^3/\mu\text{L}$	1.8 \pm 0.5	7.4 \pm 1.0	19.2 \pm 2.5
Dialab DLB5	RBC $\times 10^6/\mu\text{L}$	2.30 \pm 0.22	4.48 \pm 0.28	5.67 \pm 0.34
	HGB g/dL	5.7 \pm 0.6	13.4 \pm 0.8	18.1 \pm 1.1
	HGB g/L	57 \pm 6	134 \pm 8	181 \pm 11
	HGB mmol/L	3.5 \pm 0.4	8.3 \pm 0.5	11.2 \pm 0.8
	HCT %	16.3 \pm 2.0	36.5 \pm 2.4	49.0 \pm 3.0
	HCT L/L	0.163 \pm 0.020	0.365 \pm 0.024	0.490 \pm 0.030
	MCV fL	71.0 \pm 5.0	81.5 \pm 5.0	86.5 \pm 5.0
	MCH pg	24.8 \pm 2.5	29.9 \pm 2.5	31.9 \pm 2.8
	MCH fmol	1.54 \pm 0.16	1.85 \pm 0.17	1.98 \pm 0.19
	MCHC g/dL	34.9 \pm 3.0	36.7 \pm 3.0	36.9 \pm 3.2
	MCHC g/L	349 \pm 30	367 \pm 30	369 \pm 32
	MCHC mmol/L	21.6 \pm 2.0	22.8 \pm 2.0	22.9 \pm 2.0
	RDW %	12.0 \pm 3.0	11.5 \pm 3.0	10.5 \pm 3.0
	PLT $\times 10^3/\mu\text{L}$	66 \pm 25	250 \pm 50	530 \pm 70
	MPV fL	7.2 \pm 3.0	7.5 \pm 3.0	7.7 \pm 3.0
	PCT %	0.050 \pm 0.050	0.180 \pm 0.100	0.420 \pm 0.200
	NEU %	28.5 \pm 8.0	56.5 \pm 8.0	63.5 \pm 8.0
	LYM %	64.5 \pm 9.0	33.0 \pm 7.0	13.5 \pm 7.0
	MON %	5.5 \pm 5.0	4.5 \pm 4.5	3.0 \pm 3.0
	EO %	1.0 \pm 1.0	5.5 \pm 5.5	19.5 \pm 7.0
	BA %	0.5 \pm 0.5	0.5 \pm 0.5	0.5 \pm 0.5
	NEU $\times 10^3/\mu\text{L}$	0.5 \pm 0.2	4.2 \pm 0.6	12.2 \pm 1.6
	LYM $\times 10^3/\mu\text{L}$	1.1 \pm 0.2	2.4 \pm 0.5	2.6 \pm 1.4
	MON $\times 10^3/\mu\text{L}$	0.1 \pm 0.1	0.3 \pm 0.3	0.6 \pm 0.6
	EO $\times 10^3/\mu\text{L}$	0.1 \pm 0.1	0.4 \pm 0.4	3.7 \pm 1.4
	BA $\times 10^3/\mu\text{L}$	0.1 \pm 0.1	0.1 \pm 0.1	0.1 \pm 0.1

WBC Differential alarms may occur with control material. This will not affect the validity of results.

Before using, refer to the instruction sheet for mixing directions.

For technical assistance in the USA and Canada call Technical Service at (800) 523-3395.

All brands and products are trademarks or registered trademarks of their respective companies.